Healthcare Web Wire

Blog

Absorbable Nerve Conduits Market Trends, Growth and Regional Insights (2024 – 2034)
Absorbable Nerve Conduits Market and Strategic Analysis

The global absorbable nerve conduits market, valued at US$ 4.55 billion in 2023, is projected to reach US$ 7.38 billion by 2034, growing at a CAGR of 4.5%. The market growth is driven by the increasing demand for alternatives to autografts in repairing peripheral nerve defects, offering faster regeneration.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5314

Market Overview

The bioabsorbable nerve conduit is an elastic tubular structure exhibiting axonal growth and provides flexible easy handling, designed with specialised material that dissolves into the body to repair the nerve. The procedure does not hamper the intact nerve. The design of bioabsorbable nerve conduit encompasses two layers, the outer layer is made of poly L-lactide (PLA) multifilament fibre mesh and the inner layer is made of 50% PLA and 50% polycaprolactone (PCL) porous sponge. The combination together has the best compatible and toughening effect.

Absorbable Nerve Conduits Market Trends

Growing Preference for Biocompatible Materials: The demand for biocompatible and biodegradable materials in nerve repair is rising, as absorbable nerve conduits provide a safer and more efficient alternative to traditional autografts.

Technological Advancements: Innovations in material science, such as the development of advanced polymers and nanomaterials, are improving the performance and effectiveness of absorbable nerve conduits.

Increasing Adoption in Peripheral Nerve Repair: Absorbable nerve conduits are becoming increasingly popular in the treatment of peripheral nerve injuries, driven by their ability to support nerve regeneration and reduce the need for surgical interventions.

Growing Prevalence of Nerve Injuries: The increasing number of road accidents, sports injuries, and conditions like diabetic neuropathy is contributing to a rise in demand for nerve repair solutions, boosting market growth.

Shift Towards Minimally Invasive Procedures: The rising trend towards minimally invasive surgeries is driving the adoption of absorbable nerve conduits, as they support less invasive treatments for nerve regeneration.

Rising Investments and Research: Increased investments in medical research and clinical trials focused on improving the functionality and efficiency of nerve conduits are expected to drive innovation and market growth.

Regional Analysis

Innovation & Patient Numbers: North America to Remain a Market Leader
North America held the largest share of the absorbable nerve conduits market in 2023. This dominance is driven by the high prevalence of neurological disorders such as peripheral neuropathy, spinal cord injuries, and traumatic brain injuries. According to the Institute for Healthcare Policy and Innovation, over 20 million Americans suffer from nerve damage. National studies suggest that 13.5% of the U.S. population is affected by neuropathy, often caused by diabetes, which leads to nerve fiber damage, particularly in the legs and feet. Furthermore, 1 in 10 adults over the age of 30 experience neuropathic pain, further contributing to the demand for absorbable nerve conduits.

Healthcare Facilitation: Asia’s Growth on Track
The Asia Pacific region is expected to experience significant growth in the absorbable nerve conduits market over the coming years. This growth is driven by enhanced healthcare infrastructure, improved accessibility to healthcare services, and advancements in personalized medicine. The government of Singapore, for example, is investing heavily in healthcare services, particularly to address the needs of its aging population, which positions the country as one of the healthiest in Asia and supports the demand for nerve repair solutions.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/absorbable-nerve-conduits-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5314

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Sterile Antimicrobial Gel Market Trends, Growth and Key Insights (2024 – 2034)
Sterile Antimicrobial Gel Market Companies, Trends and Share Analysis

The global sterile antimicrobial gel market was valued at approximately USD 1.44 billion in 2023 and is expected to reach around USD 3.05 billion by 2034. This represents a robust compound annual growth rate (CAGR) of 7.05% from 2024 to 2034. The growing demand for sterile antimicrobial gels can be attributed to their essential role in preventing infections, particularly in post-surgical care, as well as in treating chronic skin ulcers, traumatic wounds, and post-operative wounds. These gels are favored for their unique combination of biocompatibility, wound healing capabilities, and disinfectant properties, making them a crucial tool in modern medical treatments.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5308

Sterile Antimicrobial Gel Market Trends

In September 2024, the U.S. Department of Health and Human Services (HHS) announced funding for the project “Transforming Antibiotic R&D with Generative AI to Stop Emerging Threats (TARGET).” This initiative, supported by the Advanced Research Projects Agency for Health, aims to enhance the development of new antibiotics using AI technology.

The G7 Finance and Health Ministers have pledged to strengthen efforts to combat antimicrobial resistance (AMR) by implementing existing strategies, addressing the market failure of antibiotics, and creating economic conditions to preserve the effectiveness of critical antibiotics.

In November 2023, the Food and Drug Administration (FDA) proposed new requirements for premarket approval applications (PMA) for certain wound dressings, including creams, gels, ointments, solid wound dressings, and liquid wound washes containing medically significant antimicrobials.

Regional Insights

Asia Pacific is experiencing the fastest growth in the sterile antimicrobial gel market, driven by factors such as a growing population, increasing medical tourism, and a rising number of traumatic injuries. China leads the region with its large population, technological advancements, and expanding demand for healthcare products and services. Germany is also contributing to market growth with its focus on developing antimicrobial wound gel products aimed at improving patient outcomes. Leading companies in the market are expanding their product offerings and engaging in strategic activities, such as new product launches, investments, mergers and acquisitions, and collaborations, to strengthen their global presence. These efforts help companies provide cost-effective solutions, ensuring their survival in a competitive market.

North America held the largest share of the sterile antimicrobial gel market in 2023, due to a high elderly population and increased rates of conditions like diabetes, burns, and traffic accidents. In Europe, the United Kingdom is at the forefront of the market, with its strong medical-focused healthcare services and solutions. Manufacturers in the region are focusing on reducing operational costs as a key business strategy. The UK-based Smith & Nephew Plc, a member of the FTSE 100 index, is a major player in the market. In 2019, they acquired Rotation Medical Inc. to advance their tissue regeneration techniques for repairing rotator cuff injuries. Research and development remain a priority for these companies as they work to develop trustworthy medical products. According to a 2020 NCBI study, approximately 40 to 50 million medical procedures are performed annually in the U.S., highlighting the growing demand for sterile antimicrobial products due to an increase in surgical procedures and hospital-acquired infections.

Key Players
- Smith & Nephew Plc: A UK-based global healthcare company known for its wound care, trauma, clinical care, and orthopedic products.
- 3M Corporation: A leading American conglomerate manufacturing a diverse range of products, including medical solutions.
Segmental Insights

Product Insights The sterile antimicrobial gel market is divided into categories such as silver dressings, povidone-iodine dressings, PHMB dressings, and others. In 2023, silver wound dressings held the largest market share. These dressings are highly effective in antimicrobial wound care, with silver as the key active ingredient. Available in various forms, including foam, gauze, hydrocolloid, and alginate, silver wound dressings are particularly beneficial for chronic wounds, such as pressure ulcers and diabetic foot ulcers, which are highly susceptible to infection.

Application Insights The market for antimicrobial wound dressings for chronic wounds was the largest in 2023. This includes treatments for conditions like pressure ulcers and lower extremity ulcers. Due to the high morbidity and mortality rates associated with chronic wounds, as well as growing public health concerns, the demand for these products is expected to continue to rise.

End-User Insights Hospitals led the market in 2023 due to the adoption of advanced tools and technologies for diagnosis, wound monitoring, and fast healing solutions. In recent years, hospitals have also focused on specialized home care services and dedicated wound care departments to manage and treat infectious conditions in patients.

Recent Developments
- 3M introduced the 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing, a solution that has been proven to eliminate catheter-related bloodstream infections.
- BSN Medical launched Cutimed® Sorbact®, a product designed to effectively treat diabetic foot ulcers, pressure ulcers, and venous leg ulcers.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/sterile-antimicrobial-gel-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5308

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Acne Medicine Market Segments, Growth and Key Companies
Acne Treatment Market Growth, Companies, and Regional Insights

The global acne treatment market, valued at US$ 13.44 billion in 2023, is projected to reach US$ 23.33 billion by 2034, growing at a CAGR of 5.14%. This growth is driven by the rising prevalence of skin issues linked to poor diet, unhealthy lifestyles, and hormonal imbalances, along with innovations in effective treatment options.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5309

Market Overview

With the changing lifestyles, people of all age groups may suffer from skin problems like acne that need proper medications and treatments to avoid the severity of those conditions. Dermatologists play major roles in providing suitable preventive measures to patients through topical medications, oral medications, or therapies. These medicines help in the reduction of produced oils and swelling due to bacterial infections or other common scenarios. Topical medications commonly include retinoids and retinoid-like drugs, antibiotics, azelaic acid and salicylic acid, or dapsone gel.

Segment Insights

Therapeutic Class Insights
In 2023, the retinoid segment led the global acne medicine market due to its widespread use and proven effectiveness in treating acne. Retinoids work by preventing clogged pores and reducing inflammation, key contributors to acne. They are commonly found in creams, gels, and lotions, making them suitable for all skin types. Popular retinoids like retinol, tretinoin, adapalene, tazarotene, and bexarotene are not only used for acne but also for treating fine wrinkles and hyperpigmentation. Dermatologists often prescribe them for mild to moderate acne cases.

Formulation Insights
The topical medication segment dominated the market in 2023, as creams, gels, and lotions are easy to apply directly to affected skin areas. In addition to retinoids, antibiotics like erythromycin and clindamycin are commonly used for topical acne treatments. These treatments can be effective for weeks or even months. A popular combination strategy involves using topical antibiotics with benzoyl peroxide and retinoids to prevent bacterial resistance.

Type Insights
Prescription medicines held the largest share in 2023, thanks to their higher concentrations of active ingredients and more advanced formulations. Oral antibiotics, like azithromycin and tetracycline, are often prescribed for acne that doesn’t respond to topical treatments. Hormonal therapies, such as oral contraceptives, are also used to control sebum production and treat acne, especially in women, adolescents, and adults.

Acne Type Insights
Non-inflammatory acne dominated the market in 2023, as it is the most common form, particularly among teenagers and young adults. Acne vulgaris can present with both inflammatory and non-inflammatory lesions. Blackheads and whiteheads, typical of non-inflammatory acne, are the most prevalent types that don’t cause swelling or irritation.

Distribution Channel Insights
Pharmacies and drug stores were the leading distribution channels in 2023, due to their widespread availability and convenience for consumers. Many acne treatments can be purchased over the counter, making them easily accessible without a prescription, which further boosts their popularity.

Recent Developments by Bausch Health Companies Inc.
- In April 2024, Bausch Health launched PrARAZLO (tazarotene lotion, 0.045%), a new topical prescription treatment for acne vulgaris, available through BC PharmaCare in British Columbia.
- In October 2023, Bausch Health received FDA approval for CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel, a first-of-its-kind combination treatment for acne vulgaris for patients aged 12 and older.
Top Companies in the Acne Medicine Market
- GlaxoSmithKline
- Bausch Health Companies Inc.
- Teva Pharmaceuticals
- Bayer AG
- Sun Pharmaceuticals
- Botanix Pharmaceuticals
- Allergan
- Zydus LifeSciences Limited
- Johnson & Johnson
- Pfizer Inc.
- Cosmo Pharmaceuticals
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/acne-medicine-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5309

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Healthcare & Medical Simulation Market Trends, Leaders and Growth Outlook
Healthcare and Medical Simulation Market: Growth Prospects and Future Trends

The healthcare and medical simulation market was valued at approximately US$ 2.14 billion in 2023 and is expected to expand to US$ 7.04 billion by 2034, reflecting a compound annual growth rate (CAGR) of 11.44% from 2024 to 2034. This growth is fueled by continuous technological innovations, increasing emphasis on patient safety, and the rising demand for high-quality healthcare treatments.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5310

Healthcare and Medical Simulation Market Trends

In August 2024, HCA Healthcare awarded a $500,000 grant to Nova Southeastern University (NSU) to establish a state-of-the-art clinical simulation lab. This funding will support NSU’s new nurse anesthesiology program, providing nursing students with access to advanced technologies in the rapidly evolving healthcare landscape.

In January 2024, Oxford Medical Simulation (OMS) announced the successful completion of a $12.6 million Series A funding round. The investment will help OMS transform healthcare education, training, and assessment through innovative simulation solutions.

Also in January 2024, GigXR, Inc. partnered with CAE Healthcare to enhance clinical simulation training. Their collaboration aims to implement and manage multimodal simulations for medical and nursing schools, hospitals, first responders, and government agencies, improving the effectiveness and efficiency of healthcare training.

Leading Companies in the Healthcare and Medical Simulation Market
1. 3D Systems, Inc.
  3D Systems is a global leader in 3D printing and simulation technology, providing innovative solutions for healthcare and medical simulation. Their advanced 3D-printed models and simulations help medical professionals with training, surgical planning, and patient-specific solutions.
2. CAE Healthcare, Inc.
  CAE Healthcare is a prominent provider of medical simulation-based training solutions. Their products include patient simulators, virtual reality training platforms, and surgical simulators, helping healthcare providers improve patient safety and enhance training for medical professionals worldwide.
3. Simulations Plus, Inc.
  Specializing in software for drug discovery and healthcare simulations, Simulations Plus provides tools for modeling and simulation in clinical development, including pharmacokinetic and pharmacodynamic modeling. Their solutions are widely used in healthcare and pharmaceutical industries to improve treatment outcomes.
4. SGMC Health
  SGMC Health is focused on developing and providing cutting-edge simulation technology for the healthcare sector. Their training solutions include virtual reality and augmented reality platforms designed to enhance the effectiveness of medical professionals’ education and skill development.
5. Oxford Medical Simulation
  Oxford Medical Simulation offers immersive, interactive, and AI-driven simulation training for healthcare professionals. Their innovative platform allows users to experience realistic medical scenarios, improving clinical skills, decision-making, and patient care.
6. GigXR, Inc.
  GigXR is known for its mixed reality-based healthcare training solutions, offering virtual reality (VR) and augmented reality (AR) simulations. Their technology is used in medical schools, hospitals, and healthcare organizations to provide hands-on training and improve clinical skills.
7. SimX
  SimX provides VR-based medical simulation solutions, offering realistic, interactive simulations for clinical training. Their platform is designed for medical professionals to practice a wide range of procedures in a controlled, risk-free virtual environment.
8. Medical-X
  Medical-X focuses on providing high-fidelity medical simulators to train healthcare professionals. Their products are used for a variety of specialties, including anesthesia, surgery, and emergency care, helping to improve hands-on training and patient safety.
9. Laerdal Medical
  Laerdal Medical is a leading company in healthcare simulation, offering a range of products designed to support training in emergency care, patient safety, and clinical procedures. Their simulation models are widely used in medical schools, hospitals, and training centers worldwide.
10. Mentice
  Mentice specializes in providing advanced simulation solutions for endovascular and cardiac procedures. Their products help healthcare professionals practice complex procedures in a realistic environment, improving surgical outcomes and patient safety.
11. Gaumard Scientific
  Gaumard Scientific provides high-fidelity patient simulators for medical education and training. Their products range from infant simulators to adult trauma and maternity simulators, all designed to help healthcare professionals improve clinical skills in various settings.
12. Simulaids
  Simulaids designs and manufactures medical training simulators, including manikins for CPR, trauma care, and other medical procedures. Their products are used in training environments to help healthcare professionals develop practical skills and improve patient outcomes.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/healthcare-and-medical-simulation-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5310

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Exploring the Plasma Fraction Market Leading Companies and Emerging Trends
Plasma Fraction Market Growth, Trends, and Key Players

The global plasma fraction market was valued at USD 32.75 billion in 2023 and is expected to reach USD 72.86 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. This growth is driven by the increasing demand for plasma-derived medicines used to treat conditions such as rabies, tetanus, shock, and trauma, further boosting the expansion of the plasma fraction industry.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5304

Market Overview

Plasma fractionation separates protein components from human blood plasma for pharmaceutical research and therapeutic uses. The rise in global diseases like immunodeficiencies and genetic disorders is driving demand for high-quality medicines, boosting the plasma fraction market. Plasma is composed of 91.5% water, 7% protein (mainly Albumin, Immunoglobulin, and Fibrinogen), and 1.5% salt.

Plasma Fraction Market Trends

In May 2024, Aegros, a biotech startup, raised $20 million to expand immunoglobulin production. In June 2024, Takeda invested $230 million to increase plasma-derived therapy production in Los Angeles.

Leading Companies in the Plasma Fraction Market

Several companies are at the forefront of the plasma fraction market, contributing to the development and production of plasma-derived therapies:

Baxter International: A global healthcare leader, Baxter focuses on innovations in plasma-based therapies, offering treatments for immunodeficiencies and other complex diseases.

Bayer: Known for its expertise in pharmaceuticals, Bayer plays a key role in the production of plasma-derived medicines, advancing treatment options in critical care.

Biotest: Specializing in immunology and hematology, Biotest manufactures plasma proteins that are used in a wide range of therapeutic applications.

BPL (Bio Products Laboratory): A key player in the market, BPL is dedicated to producing life-saving plasma therapies, especially in the areas of immunology and hematology.

CBPO (China Biologic Products): As one of China’s largest producers of plasma-derived products, CBPO focuses on high-quality therapies for chronic diseases and immunodeficiencies.

CSL Behring: A leader in plasma protein therapeutics, CSL Behring is known for its broad portfolio of life-saving treatments for rare and serious conditions.

Fusion Healthcare: A newer player in the field, Fusion Healthcare works on sustainable plasma-derived products with a focus on immunoglobulin therapies.

Grifols: A global biopharmaceutical company, Grifols is a major producer of plasma-derived therapies, including treatments for bleeding disorders and immune deficiencies.

Kedrion Biopharma Inc.: Specializing in human plasma-derived therapies, Kedrion plays a critical role in treating patients with rare diseases and immune disorders.

KM Biologics: KM Biologics is known for producing vaccines and plasma-derived products, helping to address both infectious diseases and immunological conditions.

LBF USA: A part of the LFB Group, LBF USA focuses on developing and delivering high-quality plasma-based treatments for patients worldwide.

LFB Group: Based in France, LFB is a leading producer of plasma-derived medicines, with a focus on immunology, hematology, and intensive care treatments.

Nanyue Bio: A Chinese company, Nanyue Bio specializes in plasma protein products used for treating various blood disorders and immune system conditions.

Octopharma: A Swiss company, Octopharma produces a broad range of plasma-derived therapies, focusing on hematology, immunology, and critical care.

RAAS: A prominent player in the plasma fraction market, RAAS produces therapies that are vital for treating rare diseases and chronic conditions.

Takeda Pharmaceuticals: With a strong presence in plasma-derived therapies, Takeda is a global leader in producing treatments for immune diseases and bleeding disorders.

Tiantan Bio: Based in China, Tiantan Bio focuses on producing plasma-derived products for various therapeutic areas, including immunology and hematology.

Weiguang Bio: A key company in the Chinese market, Weiguang Bio develops plasma-derived treatments for a range of medical conditions, helping improve patient outcomes worldwide.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5304

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Plasma Protein Products Market Leading Companies and Growth Trends
Plasma Protein Products Market Growth and Key Drivers

The plasma protein products market, valued at USD 32.8 billion in 2023, is projected to reach USD 72.9 billion by 2034, growing at a CAGR of 7.53%. This growth is fueled by rising cases of hematological and autoimmune disorders, increased research efforts, and greater awareness of plasma donation.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5305

Plasma Protein Products Market: From Blood to Biotech

Plasma, which makes up about 55% of blood, is the source of plasma protein products. These products are extracted through a process called fractionation, where large volumes of plasma are processed into smaller amounts of finished products. Examples include albumin, coagulation factors, fibrinolytic proteins, immunoglobulin, and clotting factors.

The growing prevalence of hematological and immunological disorders is driving the demand for plasma protein products. These products are essential in treating conditions such as bleeding disorders, trauma, hemorrhages, and coagulation deficiencies. Additionally, increased awareness of blood donations and advancements in fractionation techniques are further boosting market growth.

Top Companies in the Plasma Protein Products Market
1. ADMA Biologics, Inc.
  ADMA Biologics is a leading biopharmaceutical company that specializes in the development, manufacturing, and commercialization of plasma-derived therapies. Their portfolio includes immunoglobulins and other plasma protein-based treatments for immune deficiencies and other critical conditions.
2. BioLife
  BioLife is a prominent provider of high-quality biopharmaceuticals, particularly focusing on the collection and manufacturing of plasma-derived products. The company plays a key role in producing proteins used to treat bleeding disorders, immune system deficiencies, and other diseases.
3. Bio Products Laboratory (BPL)
  Based in the UK, BPL is a global leader in the development and supply of high-quality plasma protein products. The company specializes in producing immunoglobulins, clotting factor concentrates, and other therapeutic proteins used to treat rare and chronic conditions.
4. China Biologic Products
  China Biologic Products is one of the largest players in the plasma protein products market in China. The company is involved in the collection, processing, and distribution of human plasma-derived products, including immunoglobulin and clotting factors.
5. CSL Behring
  CSL Behring, a subsidiary of CSL Limited, is a global biotechnology company that manufactures plasma-derived therapies for treating bleeding disorders, immune deficiencies, and other serious health conditions. CSL Behring is renowned for its innovative products and has a strong presence in the global plasma protein products market.
6. Grifols S.A.
  Grifols is a Spanish multinational company that specializes in the production of plasma-derived medicines. It is one of the world’s leading providers of immunoglobulin therapies, coagulation factors, and other plasma proteins used in the treatment of hematological and immune disorders.
7. Kedrion Biopharma
  Kedrion Biopharma is an international biopharmaceutical company focused on the production of plasma-derived products. With a wide range of therapeutic products, Kedrion is a significant player in treating bleeding disorders, immunodeficiencies, and other conditions through its plasma-based therapies.
8. LFB Group
  LFB Group is a global biotechnology company that specializes in producing plasma-derived products, including immunoglobulin, clotting factors, and other proteins. LFB’s therapies are critical for the treatment of various immunological and bleeding disorders.
9. Octapharma
  Octapharma is an international human protein manufacturer, specializing in the production of plasma protein products. The company’s offerings include treatments for bleeding disorders, immune deficiencies, and other conditions that require plasma-derived therapies.
10. PlasmaGen Biosciences
  PlasmaGen Biosciences focuses on the development of innovative plasma-derived therapies for treating a wide range of diseases, particularly bleeding disorders and immune deficiencies. The company is committed to advancing the medical applications of plasma proteins.
11. Sanquin
  Sanquin is a non-profit organization based in the Netherlands, responsible for the collection, processing, and supply of blood and blood products. It is one of the key suppliers of plasma-derived therapies, focusing on immunoglobulins, clotting factors, and other essential proteins.
12. Takeda Pharmaceuticals
  Takeda Pharmaceuticals is a multinational pharmaceutical company that produces a range of plasma-derived therapies. Known for its treatments for hemophilia, immunodeficiencies, and other chronic conditions, Takeda’s plasma products are integral to global healthcare.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-protein-products-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5305

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Revolutionizing Hair Care Insights into the Hair Treatment Drug Market
Hair Treatment Drug Market Size Key Companies and Growth Strategies

The global hair treatment drug market was valued at approximately $1.4 billion in 2023 and is expected to reach around $2.99 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.14% from 2024 to 2034. This growth is primarily driven by the rising prevalence of hair loss, increased research and development efforts, and growing investments in the sector.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5306

Hair Treatment Drug Market A New Era in Hair Care

Hair loss is a common issue, with people losing more than 100 strands of hair each day. While effective treatments are available for certain types of hair loss, there are several different conditions that can cause it. These include androgenetic alopecia, alopecia areata, telogen effluvium, anagen effluvium, hypotrichosis, lichen planopilaris, and discoid lupus erythematosus, among others. Thankfully, many of these conditions can be treated with medications. Over-the-counter (OTC) options often include natural compounds like biotin, zinc, collagen, azelaic acid, and oils such as tea tree oil.

When OTC treatments aren’t enough, doctors may prescribe stronger medications like minoxidil, finasteride, spironolactone (an antiandrogen), oral contraceptives, corticosteroids, or antifungal drugs, depending on the type and severity of the hair loss.

The rising number of hair loss cases is driving the demand for hair treatment drugs. Hair loss affects both men and women of all ages, often due to factors like hormonal imbalances, immune disorders, pollution, and drug-induced hair loss. This growing issue, along with ongoing research into new treatments, is fueling the market’s expansion.

Hair Treatment Drug Market Trends

July 2024: Sun Pharma received approval from the US FDA for LEQSELVI (deuruxolitinib), a groundbreaking JAK inhibitor used to treat severe alopecia areata. This approval followed Sun Pharma’s $576 million acquisition of Concert Pharmaceuticals.

February 2024: The National Institute for Health and Care Excellence (NICE) recommended Ritlecitinib, a newly approved drug, for use by the NHS in treating severe alopecia.

June 2022: The US FDA approved Baricitinib (Olumiant), an oral treatment for alopecia areata in adults, developed by Eli Lilly.

Fiscal Q1 2024: Cipla reported a strong performance with a 18.3% increase in net profits, totaling $140.8 million. The company’s revenue also grew by 7%, driven largely by a surge in sales in North America.

Recent Developments in the Hair Treatment Drug Market

In October 2024, researchers at Harvard Medical School introduced an innovative microneedle patch system designed to deliver treatment directly to affected areas of the skin in animal models. This new system works by regulating the immune response and holds significant promise as a potential treatment for alopecia areata, as well as other conditions that require targeted immune system modulation.

In March 2024, a team from Yokohama National University in Japan explored the role of cinnamic acid, a small molecule that can activate oxytocin receptor expression, to promote hair growth in human hair follicles. The study showed promising results, indicating that products targeting oxytocin could become a new approach for promoting hair growth.

Key Companies in the Hair Treatment Drug Market

3S Bio, Inc.: A biotechnology company that focuses on the development and commercialization of innovative treatments for hair loss, particularly using biologics and small molecules.

AbbVie: A global biopharmaceutical company, AbbVie is known for its wide range of medical solutions. The company has been involved in hair loss treatments, particularly through its work on autoimmune-related alopecia areata therapies.

Aclaris Therapeutics, Inc.: A biopharmaceutical company specializing in developing treatments for dermatological conditions, including hair loss disorders. Aclaris is focused on researching new drug candidates for alopecia areata and androgenetic alopecia.

Cipla, Inc.: A multinational pharmaceutical company based in India, Cipla has a strong presence in the hair treatment market. The company offers treatments for various hair loss conditions, especially in the global markets of North America and Asia.

Daiichi Sankyo: A major Japanese pharmaceutical company involved in the research and development of therapies for various medical conditions, including hair loss. The company has been working on treatments for autoimmune disorders that cause hair loss.

Dr. Reddy’s Laboratories: An Indian multinational pharmaceutical company, Dr. Reddy’s is involved in the production and development of generic drugs and biosimilars, including products aimed at treating hair loss and related conditions.

Eli Lilly & Co.: A global leader in the pharmaceutical industry, Eli Lilly developed Baricitinib (Olumiant), the first oral treatment approved by the US FDA for alopecia areata, marking a significant advancement in hair loss treatment options.

Follicum AB: A Swedish biopharmaceutical company focused on developing treatments for hair loss, with a particular emphasis on targeting the hair follicle regeneration process. The company is working on developing peptide-based therapies for hair growth.

GlaxoSmithKline plc (GSK): A multinational pharmaceutical company with a broad portfolio that includes treatments for various hair loss conditions, including its ongoing research into novel approaches for managing alopecia areata.

Incyte Corporation: A biopharmaceutical company with a focus on immunology and oncology, Incyte has made strides in developing targeted therapies for conditions like alopecia areata. The company is actively involved in research into JAK inhibitors for hair loss.

Johnson & Johnson: One of the largest healthcare companies globally, Johnson & Johnson offers a wide range of products, including those for hair health. The company is involved in the development of both over-the-counter and prescription hair loss treatments.

Merck & Co., Inc.: A leading global pharmaceutical company, Merck has developed a number of therapies targeting autoimmune diseases and is researching ways to expand its portfolio to address conditions like alopecia areata.

Pharmacos: A pharmaceutical company focused on dermatological treatments, Pharmacos is involved in the development of topical treatments and solutions for various hair loss conditions.

Sun Pharmaceutical Industries, Ltd.: An Indian multinational pharmaceutical company, Sun Pharma has expanded its portfolio in the hair loss treatment market, particularly through its acquisition of Concert Pharmaceuticals, which added new hair loss drug candidates to its pipeline.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/hair-treatment-drug-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5306

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Artificial Nerve Conduits Market Size Key Players and Growth Prospects
Advancing Nerve Repair Artificial Nerve Conduits Market

The artificial nerve conduits market, valued at USD 2.37 billion in 2023, is projected to reach USD 5.79 billion by 2034, growing at a CAGR of 8.35%. Rising demand for innovative nerve repair solutions is driving this expansion.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5307
Market Overview

An artificial nerve conduit is a tube-like device used to repair nerve damage by connecting the two ends of a severed nerve. Current research suggests that these conduits can significantly enhance nerve regeneration, especially over distances greater than 3 cm. Unlike autografts, which are more limited and can result in complications like loss of function, painful neuromas, structural mismatches, and a shortage of graft material, artificial nerve conduits offer a solution. They can be easily customized in size and are mass-produced, making them more accessible and efficient for nerve repair.

Leading Companies in the Artificial Nerve Conduits Market

Axogen
Axogen is a prominent leader in the nerve repair industry, specializing in advanced nerve regeneration solutions. They offer a range of products designed to support nerve recovery, including their AxoGen® nerve conduits, which are used to repair peripheral nerve injuries.

Axonics
Known for its innovative technologies, Axonics focuses on developing and manufacturing devices that address nerve-related issues. While their primary focus is on sacral neuromodulation, their expertise in nerve-related medical devices positions them as an important player in the broader nerve repair market.

CollPlant Biotechnologies
CollPlant is a biotechnology company that leverages plant-based recombinant collagen for regenerative medicine, including artificial nerve conduits. Their products offer a biologically compatible and sustainable alternative to traditional nerve repair techniques.

Cook Medical
Cook Medical is a global leader in the medical device industry, offering a variety of products for nerve repair. Their nerve conduits are designed to assist in the regeneration of nerve tissues, helping to restore function following injuries.

Cytograft Tissue Engineering
Cytograft specializes in developing biologically engineered tissues for nerve repair. Their tissue-engineering technologies are aimed at improving the regeneration of nerves, making them a key player in advancing nerve conduit technology.

FibroGen
FibroGen is a biotechnology company that focuses on the discovery and development of innovative therapies for the treatment of serious diseases. They are involved in developing nerve repair solutions, including biologically engineered conduits.

Integra LifeSciences
Integra LifeSciences is a major provider of medical devices and regenerative medicine products. Their nerve repair solutions include artificial nerve conduits that are widely used for peripheral nerve reconstruction and repair.

Eton Biological
Eton Biological focuses on providing innovative medical solutions, including those for nerve repair. Their artificial nerve conduits are designed for use in the treatment of nerve injuries, offering effective regeneration solutions.

KeriMedical
KeriMedical is a specialized company involved in the development of medical devices, including those for nerve repair. Their products cater to the need for efficient and reliable nerve regeneration therapies.

Polyganics
Polyganics is a biotechnology company developing biocompatible solutions for nerve repair. Their nerve conduit products are designed to promote healing and regeneration, helping to bridge the gap in nerve injuries.

Stryker
Stryker is a leading global medical technology company, known for its broad range of products, including those for nerve repair. Their artificial nerve conduits are widely used in surgical procedures to enhance nerve regeneration after trauma.

Synaptive Medical
Synaptive Medical is known for its innovative technologies in the healthcare sector, with a focus on improving surgical outcomes. While they specialize in neurotechnology, their contributions to nerve repair, including conduits, are notable.

Synovis
Synovis, a part of the Baxter International family, specializes in surgical devices for nerve repair. They offer advanced solutions for nerve injury recovery, including their nerve conduit systems designed to promote nerve regeneration.

TheraCell
TheraCell is focused on providing tissue engineering solutions, including those for nerve repair. Their nerve conduits are designed to assist in the regeneration of peripheral nerves, improving functional recovery following injury.

Toyobo
Toyobo is a global company known for its work in biotechnology and medical technologies. They are involved in the development of artificial nerve conduits, leveraging advanced materials for nerve regeneration and repair.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/artificial-nerve-conduits-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5307

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Regional Insights and Future Trends in the Human Coagulation Factor VII Market
Understanding the Human Coagulation Factor VII Market Key Players and Emerging Trends

The global human coagulation factor VII market was valued at approximately $1.21 billion in 2023 and is expected to reach $1.82 billion by 2034, growing at a steady compound annual growth rate (CAGR) of 3.74% between 2024 and 2034. This critical therapeutic product, used to prevent bleeding, is seeing increased demand due to rising cases of accidents and trauma worldwide.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5300

Exploring Trends in the Human Coagulation Factor VII Market

In August 2024, the U.S. Food and Drug Administration announced the resolution of a shortage of NovoSeven RT, Novo Nordisk’s recombinant coagulation factor VIIa, in its 8-milligram vial form. This shortage, which began in February, has now been addressed, ensuring a steady supply of the medication.

In March 2024, TiumBio Co., Ltd., a biopharmaceutical company focused on innovative treatments for rare and challenging diseases, took a significant step forward by filing a Clinical Trial Application (CTA). This application, submitted to regulatory agencies in Spain and Italy, aims to launch a Phase 1b study for TU7710, a novel recombinant activated factor VII (rFVIIa), designed for hemophilia patients with inhibitors.

Leading Players in the Human Coagulation Factor VII Market
- Hualan Bio: A key player in the biotechnology sector, specializing in blood products and plasma-derived medicines, including coagulation factor therapies.
- Pfizer: A global pharmaceutical giant known for its broad portfolio of innovative medicines, including treatments for rare bleeding disorders.
- Bayer: Renowned for its focus on healthcare and life sciences, Bayer develops products for hemophilia and other bleeding conditions.
- Octapharma: A leader in human protein-based medicines, Octapharma focuses on blood disorders, including recombinant and plasma-derived coagulation factors.
- BPL (Bio Products Laboratory): Based in the UK, BPL specializes in plasma-derived products for the treatment of immune and bleeding disorders.
- Shire (now part of Takeda): Acquired by Takeda, Shire was a major player in rare diseases and continues to be a leader in bleeding disorder treatments under Takeda’s umbrella.
- Biogen: A biotechnology leader with a history of developing therapies for hemophilia and advancing innovative solutions for patients.
- Greencross (now part of Idexx Laboratories): Once focused on plasma products and biosciences, the company has transitioned to broader healthcare diagnostics under Idexx Laboratories.
- RAAS (China Resources and Anhui Anke Biotechnology): A Chinese company specializing in plasma-derived therapies, including coagulation factor products.
- Novo Nordisk: A global healthcare company recognized for its recombinant coagulation factor VIIa (NovoSeven), widely used to manage bleeding episodes.
- Kedrion: An Italian biopharmaceutical company producing plasma-derived therapies for rare diseases, including bleeding disorders.
- Grifols: A global leader in plasma-derived medicines and transfusion medicine, offering a range of products for blood-related conditions.
- CSL: Through its subsidiary CSL Behring, the company is a leader in innovative biotherapies, including treatments for bleeding disorders and plasma-derived therapies.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/human-coagulation-factor-vii-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5300

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024
Hepatitis A Vaccine Market Trends, Growth and Key Players
Hepatitis A Vaccine Market Growth and Key Drivers

The hepatitis A vaccine market, valued at $742.31 million in 2023, is projected to reach $948.16 million by 2034, growing at a CAGR of 2.25%. Rising outbreaks, increased immunization awareness, and expanding travel are fueling this steady growth.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5301

Hepatitis A Vaccine Market Strengthening Global Immunity

The hepatitis A vaccine is a critical tool in preventing hepatitis A, a liver infection caused by the hepatitis A virus. It is recommended for children aged 12-23 months as part of routine immunizations. The CDC also advises vaccination for people with chronic liver disease, those who use clotting factor concentrates, individuals in close contact with the virus, and communities experiencing outbreaks. The vaccine offers long-lasting protection, effective for at least 20 years, and possibly a lifetime.

With rising hepatitis A outbreaks and increasing rates of HIV and chronic liver disease, the demand for vaccines continues to grow. According to the WHO, around 354 million people worldwide are affected by hepatitis A, contributing to 1.3 million deaths annually. Supportive government policies and WHO-backed immunization guidelines are also driving the market forward.

Emerging Trends in the Hepatitis A Vaccine Market

Sanofi introduced Avaxim Junior, an inactivated hepatitis A vaccine for children aged 12 months to 15 years, in the UK in April 2023. Clinical trials across 14 countries showed the vaccine provided protection within two weeks for more than 95% of individuals.

Meanwhile, GlaxoSmithKline plc reported strong growth in 2023-24, with total sales of £30.3 billion. Vaccine sales surged by 25%, contributing to an operating profit of £6.7 billion, underscoring the rising demand for immunization solutions globally.

Top Companies in the Hepatitis A Vaccine Market
- Changchun Institute of Biological Products
- GlaxoSmithKline plc
- Indian Immunologicals Limited
- Instituto Butantan
- Janssen Vaccines
- Johnson & Johnson
- KM Biologics
- Merck & Co., Inc.
- Moderna, Inc.
- Sanofi Pasteur S.A.
- Sinopharm
- Sinovac Biotech Ltd.
- Zerun Biotech
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/hepatitis-a-vaccine-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5301

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 19, 2024